2015-08-012024-05-14https://scholars.lib.ntu.edu.tw/handle/123456789/657751摘要：為預防器官移植患者發⽣生肺炎鏈球菌感染，美國成⼈人疫苗接種諮詢委員會建議患者應接種1 劑13 價蛋⽩白接合型肺炎鏈球菌疫苗，並於⾄至少8 周後再⾏行施打23 價多醣體肺炎鏈球菌疫苗。︒｡但⽬目前相關研究仍關研究甚少。︒｡故本研究欲評估器官移植患者/候選者施打13 價蛋⽩白接合型肺炎鏈球菌疫苗後，產⽣生免疫功能的狀況及安全性。︒｡本研究收納接受移植評估時，臨床狀況穩定之器官移植候選者及移植六個⽉月後，臨床狀況穩定之器官移植患者，給予⼀一劑13 價蛋⽩白接合型肺炎鏈球菌疫苗。︒｡本研究紀錄施打後七天內發⽣生的症狀，及測量施打前，施打後⼀一、︑､三、︑､六、︑､九、︑､⼗十⼆二個⽉月對四種⾎血清型(6B, 14, 19F and 23F)產⽣生的抗體效價。︒｡陽性抗體反應定義為施打後⾎血清型抗體效價和施打疫苗前的抗體效價(即基礎值)相⽐比，有兩倍或以上的上升，且抗體效價需⼤大於等於1000 ng/ml 。︒｡⽐比較移植前和移植後給予13 價蛋⽩白接合型肺炎鏈球菌疫苗的安全性和有效性。︒｡<br> Abstract: Because of long-term use of immunosuppressants, solid-organ transplant recipients had a significantlyhigher incidence rate (146 infections per 100000 persons per year) of invasive pneumococcal disease,including pneumonia, bacteremia, and meningitis, than the general population (11.5 per 100000 persons peryear, p < 0.00001). The immunogenicity of pneumococcal vaccine (PPV23) in solid organ transplantrecipients was generally suppressed. The 13-valent conjugate pneumococcal vaccines (PCV13) have beendeveloped in order to enhance the immunogenicity of the polysaccharide vaccine, and has been proofedeffective in children aged 6 weeks to 5 years and adults aged >50 years. The Advisory Committee onImmunization Practices (ACIP) recommended that solid organ transplant recipients should receive a dose ofPCV13 first, followed by a dose of PPV23 at least 8 weeks later, but there are no clinical data regarding itsuse in solid organ transplant recipients. Thus the present study aims to evaluate the safety andimmunogenicity of PCV13 use in solid organ transplant candidates/recipients and compare theimmunogenicity of PCV13 before and after transplantation.